1. Home
  2. AVB vs ILMN Comparison

AVB vs ILMN Comparison

Compare AVB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVB

AvalonBay Communities Inc.

HOLD

Current Price

$169.54

Market Cap

22.5B

Sector

Real Estate

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$120.02

Market Cap

19.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVB
ILMN
Founded
1978
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
19.4B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
AVB
ILMN
Price
$169.54
$120.02
Analyst Decision
Hold
Hold
Analyst Count
15
17
Target Price
$198.20
$124.24
AVG Volume (30 Days)
948.5K
1.3M
Earning Date
04-27-2026
04-30-2026
Dividend Yield
4.22%
N/A
EPS Growth
N/A
170.87
EPS
7.40
5.45
Revenue
$3,040,725,000.00
$4,343,000,000.00
Revenue This Year
$4.04
$6.52
Revenue Next Year
$5.03
$5.60
P/E Ratio
$22.76
$22.71
Revenue Growth
4.36
N/A
52 Week Low
$160.10
$69.88
52 Week High
$213.34
$155.53

Technical Indicators

Market Signals
Indicator
AVB
ILMN
Relative Strength Index (RSI) 54.61 43.87
Support Level $167.78 $115.45
Resistance Level $181.72 $128.96
Average True Range (ATR) 2.94 5.01
MACD 1.10 0.14
Stochastic Oscillator 91.01 26.32

Price Performance

Historical Comparison
AVB
ILMN

About AVB AvalonBay Communities Inc.

AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: